{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:24:16Z","timestamp":1771557856926,"version":"3.50.1"},"reference-count":8,"publisher":"National Institute of Public Health NIH (National Research Institute)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Przegl Epidemiol"],"abstract":"<p><strong>ABSTRACT<\/strong><br \/><strong>INTRODUCTION.<\/strong> Lyme borreliosis, also known as Lyme disease, is a zoonotic disease transmitted by ticks.\u00a0<br \/>The infection occurs through a bite by a common tick (Ixodes ricinus). Due to the annual cycle of tick activity,\u00a0mainly dependent on temperature, Lyme disease is seasonal. In certain cases, post-exposure prophylaxis may\u00a0be indicated, while the vaccine is in phase III clinical trials.<br \/><strong>AIM OF THE STUDY.<\/strong> The aim of the study is to assess the epidemiological situation of Lyme disease in\u00a0Poland in 2020 compared to the situation in previous years.<br \/><strong>MATERIAL AND METHODS.<\/strong> The epidemiological situation of Lyme disease in Poland was assessed on the\u00a0basis of the data sent to NIPH NIH \u2013 NRI by voivodeship sanitary-epidemiological stations and published in the\u00a0bulletin \u201cInfectious diseases and poisoning in Poland in 2020\u201d.<br \/><strong>RESULTS.<\/strong> In 2020, 12,934 Lyme borreliosis cases and 459 hospitalizations were registered which, compared\u00a0to 2019, means a 37.3% decrease in morbidity and a 73% decrease in hospitalization. It may be related to\u00a0the outbreak of the SARS-CoV-2 virus at the end of 2019, which reached Poland at the beginning of March\u00a02020. It can be seen that in Q2, due to the lower activity of people due to the epidemic, the number of cases of\u00a0Lyme disease was less than in Q1 (2,064 in Q2 compared to 2,253 in Q1). The decrease compared to 2019 also\u00a0continued in the third and fourth quarter, by 28% and 49%, respectively.<br \/><strong>SUMMARY AND CONCLUSION.<\/strong> The impact of the SARS-CoV-2 outbreak on the distribution of Lyme\u00a0disease incidence is noticeable, in particular on the decrease in the overall number of cases during the year,\u00a0as well as on hospitalization due to Lyme disease with the previously observed stabilization of the incidence.<br \/>The pandemic could have influenced this state of affairs on various levels. The main reason was, of course, the\u00a0introduction of the epidemic and the related restrictions (including reduced mobility), but it cannot be ruled\u00a0out that the cause was not an excessive burden on the health care system and sanitary inspection (delay in\u00a0registration of reports).<\/p>\n<p><strong>STRESZCZENIE<\/strong><br \/><strong>WST\u0118P.<\/strong> Borelioza, inaczej zwana chorob\u0105 z Lyme, jest chorob\u0105 odzwierz\u0119c\u0105 (zoonoz\u0105) przenoszon\u0105 przez\u00a0kleszcze. Do zaka\u017cenia dochodzi poprzez pok\u0142ucie przez kleszcza pospolitego (Ixodes ricinus). W zwi\u0105zku\u00a0z cyklem aktywno\u015bci kleszczy w ci\u0105gu roku, zale\u017cnym g\u0142\u00f3wnie od temperatury, borelioza wykazuje sezonowo\u015b\u0107.\u00a0W okre\u015blonych przypadkach mo\u017ce by\u0107 wskazana profilaktyka poekspozycyjna, natomiast szczepionka\u00a0jest w trakcie III fazy bada\u0144 klinicznych.<br \/><strong>CEL PRACY.<\/strong> Celem pracy jest ocena sytuacji epidemiologicznej boreliozy w Polsce w 2020 r. w por\u00f3wnaniu\u00a0do sytuacji w latach ubieg\u0142ych.<br \/><strong>MATERIA\u0141 I METODY.<\/strong> Do przeprowadzenia oceny sytuacji epidemiologicznej boreliozy w Polsce wykorzystano\u00a0dane nadsy\u0142ane do NIZP PZH \u2013 PIB przez Wojew\u00f3dzkie Stacje Sanitarno-Epidemiologiczne i publikowane\u00a0w biuletynie rocznym: \u201eChoroby zaka\u017ane i zatrucia w Polsce w 2020 r.<br \/><strong>WYNIKI.<\/strong> W 2020 r. odnotowano 12 934 zachorowania na borelioz\u0119 oraz 459 hospitalizacji z powodu tej choroby,\u00a0co w por\u00f3wnaniu do 2019 r. oznacza spadek zachorowa\u0144 o 37,3% oraz spadek hospitalizacji o 73%. Spadki\u00a0te mog\u0105 mie\u0107 zwi\u0105zek z wybuchem epidemii COVID-19 pod koniec 2019 r., kt\u00f3ra w Polsce rozpocz\u0119\u0142a si\u0119 na\u00a0pocz\u0105tku marca 2020 r. W II kwartale, liczba zachorowa\u0144 na borelioz\u0119 wynios\u0142a mniej ni\u017c w I kwartale (2 064\u00a0w II kwartale w por\u00f3wnaniu do 2 253 w I kwartale). Spadek w stosunku do 2019 r. utrzyma\u0142 si\u0119 r\u00f3wnie\u017c w III\u00a0i IV kwartale, odpowiednio o 28% i 49%.<br \/><strong>PODSUMOWANIE I WNIOSKI.<\/strong> Zauwa\u017calny jest wp\u0142yw epidemii SARS-CoV-2 na rozk\u0142ad zachorowa\u0144 na\u00a0borelioz\u0119, w szczeg\u00f3lno\u015bci na spadek og\u00f3lnej liczby przypadk\u00f3w w ci\u0105gu roku, jak i hospitalizacji z powodu boreliozy\u00a0przy poprzednio obserwowanej stabilizacji zapadalno\u015bci. Pandemia mog\u0142a wp\u0142yn\u0105\u0107 na taki stan rzeczy\u00a0na r\u00f3\u017cnych p\u0142aszczyznach. G\u0142\u00f3wn\u0105 przyczyn\u0105 by\u0142o oczywi\u015bcie wprowadzenie stanu epidemii oraz zwi\u0105zane\u00a0z tym restrykcje (w tym ograniczenie mobilno\u015bci), jednak nie mo\u017cna wykluczy\u0107, \u017ce przyczyn\u0105 nie by\u0142o nadmierne\u00a0obci\u0105\u017cenie systemu opieki zdrowotnej i inspekcji sanitarnej (op\u00f3\u017anienie rejestracji zg\u0142osze\u0144).<\/p><\/jats:p>","DOI":"10.32394\/pe.76.36","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T14:50:17Z","timestamp":1671115817000},"page":"385-390","source":"Crossref","is-referenced-by-count":3,"title":["Lyme disease in Poland in 2020"],"prefix":"10.32394","volume":"76","author":[{"given":"J","family":"Zbrze\u017aniak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Paradowska-Stankiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17323","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"ref0","unstructured":"Zajkowska J, Garkowski A. Borelioza. W: Zajkowska J. red. Atlas choroby odkleszczowe i inne choroby OUN. Warszawa: Medical Tribune Polska; 2021, 25-28."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Eldin C, Raffetin A, Bouiller K, et al. Review of European and American guidelines for the diagnosis of Lyme borreliosis. Med Mal Infect 2019;49(2):121-132. doi: 10.1016\/j.medmal.2018.11.011.","DOI":"10.1016\/j.medmal.2018.11.011"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Kmieciak W, Ciszewski M, Szewczyk EM. Tick-borne diseases in Poland: Prevalence and difficulties in diagnostics. Medycyna Pracy 2016;67(1):73-87.","DOI":"10.13075\/mp.5893.00264"},{"key":"ref3","unstructured":"Pancewicz S, Moniuszko-Malinowska A, Garlicki A, et al. Diagnostyka i leczenie boreliozy z Lyme. Standardy Polskiego Towarzystwa Epidemiolog\u00f3w I Lekarzy Chor\u00f3b Zaka\u017anych. [Internet] Available from: http:\/\/www.pteilchz.org.pl\/wp-content\/uploads\/2018\/11\/borelioza_z_lyme_2018.pdf"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kullberg B. J, Vrijmoeth H. D, van de Schoor F et al. W. Lyme borreliosis: diagnosis and management. BMJ 2020;369: :m1041 doi: https:\/\/doi.org\/10.1136\/bmj.m1041","DOI":"10.1136\/bmj.m1041"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15. [Internet] Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-valneva-initiate-phase-3-study-lyme-disease","DOI":"10.47287\/cen-10023-buscon17"},{"key":"ref6","unstructured":"Czarkowski MP, et al. Choroby zaka\u017ane i zatrucia w Polsce w 2020 roku. NIZP-PZH, GIS, Warszawa 2021"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zbrze\u017aniak J, Paradowska-Stankiewicz I. Lyme disease in Poland in 2019 \/ Borelioza z Lyme w Polsce w 2019 roku. Przegl Epidemiol 2021,75(2):210-214","DOI":"10.32394\/pe.75.19"}],"container-title":["Przeglad Epidemiologiczny"],"original-title":["Borelioza z Lyme w Polsce w 2020 roku"],"link":[{"URL":"https:\/\/www.przeglepidemiol.pzh.gov.pl\/pdf-181080-101641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.przeglepidemiol.pzh.gov.pl\/pdf-181080-101641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T08:43:54Z","timestamp":1709887434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.przeglepidemiol.pzh.gov.pl\/Lyme-disease-in-Poland-in-2020,181080,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"alternative-id":["181080"],"URL":"https:\/\/doi.org\/10.32394\/pe.76.36","relation":{},"ISSN":["0033-2100","2545-1898"],"issn-type":[{"value":"0033-2100","type":"print"},{"value":"2545-1898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]}}}